WASHINGTON - FDA has published a final regulation on financial disclosure that requires any applicant who submits a marketing application for a drug, biological product or device to disclose whether the clinical investigators have financial interests that could affect the reliability of the submissions. The rule, which becomes effective in February 1999, addresses concerns that clinical data submitted in support of a product application might be influenced by